Biocon Biologics has demonstrated success and established global credibility with several of its molecules being approved and launched in both developed and emerging markets. The Company is at an important inflection point as it gains commercial success with its first wave of products and invests in long term sustainability through broadening of its pipeline and commercial presence, further expanding manufacturing scale, and two strategic transactions with Serum Institute Life Sciences and Viatris.

You can read about how Biocon Biologics is evolving as a brand as it focuses, invests, competes and wins in the large and growing opportunity from biosimilars worldwide.